C4 Therapeutics CCCC 深 沪
等待开盘 12-18 09:30:00 美东时间
2.05
-0.210
-9.29%
华盛通- 最 高2.30
- 今 开2.30
- 成交量 175.96万股
- 最 低 2.0401
- 昨 收 2.26
- 总市值 1.46亿
- 52周最高 4.26
- 市盈率 静 --
- 换手率 2.47%
- 52周最低 1.085
- 委 比 99.04%
- 总股本 7117.08万
- 历史最高 51.21
- 量 比 1.64
- 振 幅 11.50%
- 历史最低 1.06
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
今天 10:54
Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5
Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.
今天 01:36
期权扫描 | 特朗普新政All in机器人领域！特斯拉多张Call单飙升超4倍；微软期权放量近2倍
特朗普新政All in机器人领域！特斯拉公布重大技术突破，多张Call单飙升超4倍；微软期权放量近2倍；比特币重回9.3万美元，MSTR期权成交活跃>>
12-04 13:48
TD Cowen Initiates Coverage On C4 Therapeutics with Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Buy rating.
12-02 20:20
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
C4 Therapeutics, Inc. (C4T) announced that its management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 3:25 pm ET in Coral Gables, Florida. A live webcast and replay will be available on the company’s Investor Relations website. C4T is a clinical-stage biopharmaceutical company focused on targeted protein degradation science to develop innovative therapies for difficult-to-treat dise...
11-25 12:00
C4 Therapeutics files $400M mixed shelf offering
C4 Therapeutics (CCCC) has filed a shelf registration to offer up to $400M in securities. The offering may include common stock, preferred stock, debt securities, warrants, or units, in one or more co...
11-22 06:15
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
C4 Therapeutics reported a $125 million equity offering, extending its runway to late 2028. Notable achievements include strong Phase 1 data for cemsidomide in multiple myeloma with a 53% overall response rate, a collaboration with Pfizer to combine cemsidomide with elranatamab, and plans to initiate Phase 2 and Phase 1b trials in early 2026. The company remains focused on advancing cemsidomide's development and progressing its pipeline of target...
11-06 12:00
Precision Oncology Approaches Drive $312B Market Transformation
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates ...
10-17 21:00
美股牛股 | PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；生物技术股WHWK涨超24%
PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；WHWK涨超24%，与Tempus AI建立战略伙伴关系，共同推进肿瘤研究领域发展>>
10-17 17:43
